Ebola virus (EBOV) infection: Therapeutic strategies

Within less than a year after its epidemic started (in December 2013) in Guinea, Ebola virus (EBOV), a member of the filoviridae, has spread over a number of West-African countries (Guinea, Sierra Leone and Liberia) and gained allures that have been unprecedented except by human immunodeficiency vir...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 2015-01, Vol.93 (1), p.1-10
Main Author: De Clercq, Erik
Format: Article
Language:English
Subjects:
3-Deazaneplanocin A
Africa, Western - epidemiology
Animals
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
BCX4430
Ebola
Ebola virus
Ebolavirus - drug effects
Ebolavirus - physiology
Favipiravir
Filoviridae
Hemorrhagic Fever, Ebola - drug therapy
Hemorrhagic Fever, Ebola - epidemiology
Hemorrhagic Fever, Ebola - transmission
Humans
Rhabdoviridae
Vesicular stomatitis virus
VSV (vesicular stomatitis virus)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Within less than a year after its epidemic started (in December 2013) in Guinea, Ebola virus (EBOV), a member of the filoviridae, has spread over a number of West-African countries (Guinea, Sierra Leone and Liberia) and gained allures that have been unprecedented except by human immunodeficiency virus (HIV). Although EBOV is highly contagious and transmitted by direct contact with body fluids, it could be counteracted by the adequate chemoprophylactic and -therapeutic interventions: vaccines, antibodies, siRNAs (small interfering RNAs), interferons and chemical substances, i.e. neplanocin A derivatives (i.e. 3-deazaneplanocin A), BCX4430, favipiravir (T-705), endoplasmic reticulum (ER) α-glucosidase inhibitors and a variety of compounds that have been found to inhibit EBOV infection blocking viral entry or by a mode of action that still has to be resolved. Much has to be learned from the mechanism of action of the compounds active against VSV (vesicular stomatitis virus), a virus belonging to the rhabdoviridae, that in its mode of replication could be exemplary for the replication of filoviridae.
ISSN:0006-2952
1873-2968
1873-2968
DOI:10.1016/j.bcp.2014.11.008